- Scientists are developing a new type of immunotherapy for cancer treatment called Tri-specific killer engagers (TriKEs).
- TriKEs are designed to activate natural killer (NK) cells, which are a type of immune cell that can kill cancer cells.
- They are made up of three parts: one part that binds to NK cells, another part that binds to cancer cells, and a third part that helps to activate NK cells.
- TriKEs have shown promising results in early studies and are expected to be a powerful new tool for cancer immunotherapy.
Funding
- Not applicable.
Original Paper
Title of original paper: Tri-specific killer engager: unleashing multi-synergic power against cancer
Journal: Exploration of Targeted Anti-tumor Therapy
DOI: https://doi.org/10.37349/etat.2024.00227